Insmed Incorporated Common Stock (INSM)

FairStock Score: 39/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style bargain hunter and a Buffett-style student of durable economics, and Insmed does not fit the classic mold. The business sells therapies for serious rare diseases, and the top line is moving fast: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $425.5M and net loss was $13.2M, or diluted EPS of -$0.06. That compares with fiscal Q2 2025, the quarter ended 2025-06-30, when revenue was $107.4M, net loss was $321.7M, and diluted EPS was -$1.70. So the latest quarter shows dramatic revenue growth and a much smaller loss. However, the longer record is still loss-making. Fiscal FY2025, ended 2025-12-31, had revenue of $606.4M, net loss of $1.3B, and diluted EPS of -$6.42. Fiscal FY2024 had revenue of $363.7M and net loss of $913.8M. Fiscal FY2023 had revenue of $305.2M and net loss of $749.6M. Free cash flow is -$807.7M trailing, and the FairStock FCF yield is -3.8%. At the 2026-10-13 close of $96.79, the FairStock P/E is -23.49, P/B is 27.89, ROE is -87.22%, ROCE is -22.17%, and D/E is 0.98. The FairStock Piotroski F-Score is 3/9, Altman Z-Score is 6.28, and FairStock Score is 39/100. The Lynch category is none because the company has lost money in each of the last four years. There may be a rare-disease moat if approved therapies gain exclusivity and pricing power, but today the numbers offer no margin of safety. The price is a wager on future profits, not a Graham bargain.

In plain English: Insmed is a healthcare company that makes and tests medicines for rare and serious diseases. Sales are growing very quickly, and it lost much less money in its latest quarter than a year earlier, but it still has not made a profit and spends a lot of cash. At the recent price, the shares look expensive compared with the company’s current profits and assets, so the price depends heavily on future medicines succeeding.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer